The Committee For Medicinal Products For Human Use Of The European Medicines Agency Adopted A Positive Opinion For Pfizer's Fidanacogene Elaparvovec, A One-time Gene Therapy For Severe Hemophilia B In Adult Patients
The Committee For Medicinal Products For Human Use Of The European Medicines Agency Adopted A Positive Opinion For Pfizer's Fidanacogene Elaparvovec, A One-time Gene Therapy For Severe Hemophilia B In Adult Patients
歐洲藥品管理局人用藥品委員會對輝瑞的Fidanacogene Elaparvovec通過了積極的看法，這是一種針對成年患者嚴重乙型血友病的一次性基因療法
The Committee For Medicinal Products For Human Use Of The European Medicines Agency Adopted A Positive Opinion For Pfizer's Fidanacogene Elaparvovec, A One-time Gene Therapy For Severe Hemophilia B In Adult Patients
歐洲藥品管理局人用藥品委員會對輝瑞的Fidanacogene Elaparvovec通過了積極的看法，這是一種針對成年患者嚴重乙型血友病的一次性基因療法
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。